Early lesion detection with 18F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer

被引:46
作者
Wondergem, M. [1 ]
Jansen, B. H. E. [2 ,3 ]
van der Zant, F. M. [1 ]
van der Sluis, T. M. [2 ]
Knol, R. J. J. [1 ]
van Kalmthout, L. W. M. [4 ]
Hoekstra, O. S. [3 ]
van Moorselaar, R. J. A. [2 ]
Oprea-Lager, D. E. [3 ]
Vis, A. N. [2 ]
机构
[1] Noordwest Ziekenhuisgroep, Nucl Med, Wilhelminalaan 12, NL-1815 JD Alkmaar, Netherlands
[2] Vrije Univ Amsterdam, Amsterdam Univ, Med Ctr, Urol, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands
[3] Vrije Univ Amsterdam, Amsterdam Univ, Med Ctr, Radiol & Nucl Med, Amsterdam, Netherlands
[4] Univ Med Ctr Utrecht, Radiol & Nucl Med, Utrecht, Netherlands
关键词
F-18-DCFPyL PET; CT; Biochemically recurrent; Prostate cancer; PSMA; MEMBRANE ANTIGEN; RADICAL PROSTATECTOMY; CONSENSUS; RECOMMENDATIONS; GUIDELINES; THERAPY; MEN;
D O I
10.1007/s00259-019-04385-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PurposeProstate-specific membrane antigen (PSMA) PET/CT is increasingly used in patients with biochemically recurrent prostate cancer (BCR), mostly using gallium-68 (Ga-168)-labelled radiotracers. Alternatively, fluorine-18 (F-18)-labelled PSMA tracers are available, such as F-18-DCFPyL, which offer enhanced image quality and therefore potentially increased detection of small metastases. In this study we evaluate the lesion detection efficacy of F-18-DCFPyL PET/CT in patients with BCR and determine the detection efficacy as a function of their PSA value.MethodsA total of 248 consecutive patients were evaluated and underwent scanning with F-18-DCFPyL PET/CT for BCR between November 2016 and 2018 in two hospitals in the Netherlands. Patients were examined after radical prostatectomy (52%), external-beam radiation therapy (42%) or brachytherapy (6%). Imaging was performed 120min after injection of a median dose of 311MBq F-18-DCFPyL.ResultsIn 214 out of 248 PET/CT scans (86.3%), at least one lesion suggestive of cancer recurrence was detected (positive scan'). Scan positivity increased with higher PSA values: 17/29 scans (59%) with PSA values <0.5ng/ml; 20/29 (69%) with PSA 0.5 to<1.0ng/ml; 35/41 (85%) with PSA 1.0 to<2.0ng/ml; 69/73 (95%) with PSA 2.0 to<5.0ng/ml; and 73/76 (96%) with PSA >= 5.0ng/ml. Interestingly, suspicious lesions outside the prostatic fossa were detected in 39-50% of patients with PSA <1.0ng/ml after radical prostatectomy (i.e. candidates for salvage radiotherapy).Conclusion(18)F-DCFPyL PET/CT offers early detection of lesions in patients with BCR, even at PSA levels <0.5ng/ml. These results appear to be comparable to those reported for Ga-68-PSMA and F-18-PSMA-1007, with potentially increased detection efficacy compared to Ga-68-PSMA for patients with PSA <2.0.
引用
收藏
页码:1911 / 1918
页数:8
相关论文
共 30 条
[1]   Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer [J].
Afshar-Oromieh, Ali ;
Debus, Nils ;
Uhrig, Monika ;
Hope, Thomas A. ;
Evans, Michael J. ;
Holland-Letz, Tim ;
Giesel, Frederik L. ;
Kopka, Klaus ;
Hadaschik, Boris ;
Kratochwil, Clemens ;
Haberkorn, Uwe .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (12) :2045-2054
[2]   Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point? [J].
Amling, CL ;
Bergstralh, EJ ;
Blute, ML ;
Slezak, JM ;
Zincke, H .
JOURNAL OF UROLOGY, 2001, 165 (04) :1146-1151
[3]   A Systematic Review of the Role of Imaging before Salvage Radiotherapy for Post-prostatectomy Biochemical Recurrence [J].
Beresford, M. J. ;
Gillatt, D. ;
Benson, R. J. ;
Ajithkumar, T. .
CLINICAL ONCOLOGY, 2010, 22 (01) :46-55
[4]   2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer [J].
Chen, Ying ;
Pullambhatla, Mrudula ;
Foss, Catherine A. ;
Byun, Youngjoo ;
Nimmagadda, Sridhar ;
Senthamizhchelvan, Srinivasan ;
Sgouros, George ;
Mease, Ronnie C. ;
Pomper, Martin G. .
CLINICAL CANCER RESEARCH, 2011, 17 (24) :7645-7653
[5]   Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer update panel report and recommendations for a standard in the reporting of surgical outcomes [J].
Cookson, Michael S. ;
Aus, Gunnar ;
Burnett, Arthur L. ;
Canby-Hagino, Edith D. ;
D'Amico, Anthony V. ;
Dmochowski, Roger R. ;
Eton, David T. ;
Forman, Jeffrey D. ;
Goldenberg, S. Larry ;
Hernandez, Javier ;
Higano, Celestia S. ;
Kraus, Stephen R. ;
Moul, Judd W. ;
Tangen, Catherine ;
Thrasher, J. Brantley ;
Thompson, Ian .
JOURNAL OF UROLOGY, 2007, 177 (02) :540-545
[6]  
Cornford PBJ, 2019, EAU ESTRO SIOG GUIDE
[7]   EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer [J].
Cornford, Philip ;
Bellmunt, Joaquim ;
Bolla, Michel ;
Briers, Erik ;
De Santis, Maria ;
Gross, Tobias ;
Henry, Ann M. ;
Joniau, Steven ;
Lam, Thomas B. ;
Mason, Malcolm D. ;
van der Poel, Henk G. ;
van der Kwast, Theo H. ;
Rouviere, Olivier ;
Wiegel, Thomas ;
Mottet, Nicolas .
EUROPEAN UROLOGY, 2017, 71 (04) :630-642
[8]   PSA-Stratified Performance of 18F- and 68Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer [J].
Dietlein, Felix ;
Kobe, Carsten ;
Neubauer, Stephan ;
Schmidt, Matthias ;
Stockter, Simone ;
Fischer, Thomas ;
Schomaecker, Klaus ;
Heidenreich, Axel ;
Zlatopolskiy, Boris D. ;
Neumaier, Bernd ;
Drzezga, Alexander ;
Dietlein, Markus .
JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (06) :947-952
[9]   Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT [J].
Eiber, Matthias ;
Herrmann, Ken ;
Calais, Jeremie ;
Hadaschik, Boris ;
Giesel, Frederik L. ;
Hartenbach, Markus ;
Hope, Thomas ;
Reiter, Robert ;
Maurer, Tobias ;
Weber, Wolfgang A. ;
Fendler, Wolfgang P. .
JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (03) :469-478
[10]   Treatment Outcomes from 68Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET [J].
Emmett, Louise ;
van Leeuwen, Pim J. ;
Nandurkar, Rohan ;
Scheltema, Matthijs J. ;
Cusick, Thomas ;
Hruby, George ;
Kneebone, Andrew ;
Eade, Thomas ;
Fogarty, Gerald ;
Jagavkar, Raj ;
Quoc Nguyen ;
Bao Ho ;
Joshua, Anthony M. ;
Stricker, Phillip .
JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (12) :1972-1976